Revenue + Forward P/E
Boston Scientific Corporation (BSX) quarterly revenue and forward P/EForward P/E: 15.5x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$76.43B
Enterprise value
$75.28B
P/E ratio (TTM)
18.44x
P/S ratio (TTM)
3.19x
P/B ratio
2.54x
EV/Sales
3.65x
EV/EBITDA
13.30x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$20.07B
Gross profit (TTM)
$13.85B
Operating income (TTM)
$3.97B
EBITDA (TTM)
$5.10B
Net income (TTM)
$2.89B
Free cash flow (TTM)
$3.66B
Margins & returns
Gross margin
70.41%
Operating margin
20.12%
Profit margin
17.24%
Return on equity
14.82%
Return on assets
8.01%
Per-share metrics
EPS (TTM)
$2.39
Dividend yield
0.00%
Beta
0.58
Capital structure
Cash & equivalents
$2.04B
Total debt
$12.42B
Net debt
$10.37B
Shares outstanding
1.49B
Financial health
Current ratio
1.62
Debt / equity
0.51
Debt / assets
0.28
Interest coverage
11.38
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $628.65B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $439.33B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $368.33B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $357.27B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $328.31B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $76.43B | 18.44x | 3.19x | 13.30x | - |